07
Feb
2012
Posted in I - Series A, Q - 4Q11, R - ROCKY MOUNTAIN, X - Device (Diagnostic), XX - UT
Sera Prognostics (Salt Lake City, UT) a development-stage diagnostic company focused on preterm birth and other pregnancy complications, closed a $19.3M Series A financing. Participants include InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners.
16
Jan
2012
Posted in I - Series C, Q - 3Q11, R - ROCKY MOUNTAIN, X - BioAcrylic, X - Biofuel, XX - CO
OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital.
Thanx for your patience as we catch-up.
08
Nov
2011
08
Nov
2011
08
Nov
2011
28
Mar
2011
Posted in I - Series A, Q - 1Q11, R - ROCKY MOUNTAIN, X - Inflammation, X - Pain, XX - CO
PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.
03
Jan
2011
Posted in I - Series D, Q - 4Q10, R - ROCKY MOUNTAIN, X - Alzheimer's, X - Medical Food, XX - CO
Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.
11
Nov
2010
Posted in I - Series C, Q - 4Q10, R - ROCKY MOUNTAIN, X - Device (Diagnostic), X - Oncology, XX - CO
Biodesix (Broomfield, CO) a commercial-stage personalized medicine company focused on diagnostic products that inform treatment decisions and patient care, whose initial product, VeriStrat, predicts response to the targeted therapy erlotinib in patients with advanced NSCLC, closed a $7.1M Series C financing. Participants were not identified.
07
Sep
2010
Posted in I - Series A, Q - 3Q10, R - ROCKY MOUNTAIN, X - Autism, X - Device (Diagnostic), XX - UT
Lineagen (Salt Lake City, UT) a development stage content-based biomarker discovery company focused on diagnostic tests for autism, multiple sclerosis and COPD, closed a $5M Series A, bringing the total round to $10.8M. Participants include PrairieGold Venture Partners, vSpring Capital, Sanderling Ventures and Mesa Verde Venture Partners.
12
Jul
2010
Posted in I - Series B, Q - 2Q10, R - ROCKY MOUNTAIN, X - Asthma, X - COPD, X - IBD, XX - CO
N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.
12
Apr
2010
Posted in I - Series E, Q - 1Q10, R - ROCKY MOUNTAIN, X - Hepatitis C, X - Oncology, X - Vaccines, XX - CO
GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK [...]
12
Oct
2009
Posted in I - Series B, Q - 3Q09, R - ROCKY MOUNTAIN, X - Device (Cardiology), XX - UT
Coherex Medical (Salt Lake City, UT) a development-stage medical device company focused on the Flatstent™ EF PFO Closure System used to close patent foramen ovale heart defects, closed a $16.5M Series B financing. Participants include Oxford Bioscience Partners, vSpring Capital and Tullis Health Investors.
07
Jul
2009